Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: Placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers

Toyota, Takayoshi; Hirata, Yoshinari; Ikeda, Yoshifumi; Matsuoka, Katsuyoshi; Sakuma, Atsushi; Mizushima, Yutaka

doi:10.1016/0090-6980(93)90081-h

Cited by 45 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since 1988, a new preparation of PGE1, ‘lipo‐PGE1,’ has been used in Japan for the treatment of intermittent claudication and thrombangitis obliterans 8,18 . The lipid component consists of an emulsion of purified soybean oil and yolk lecithin with homogeneous micelles of about 0.2 µm in diameter; these micelles contain the PGE1.…”

Section: Discussionmentioning

confidence: 99%

“…Since 1988, a new preparation of PGE1, 'lipo-PGE1,' has been used in Japan for the treatment of intermittent claudication and thrombangitis obliterans. 8,18 The lipid component consists of an emulsion of purified soybean oil and yolk lecithin with homogeneous micelles of about 0.2 mm in diameter; these micelles contain the PGE1. In both animal experiments and controlled studies with healthy volunteers, the intravenous bolus injection of lipo-PGE1 exhibited the same efficacy and therapeutic safety as a 2-hour infusion of conventional PGE1-cyclodextri.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long beneficial effects after lipo-prostaglandin E1 administration on the ischemic gastric tube in pigs

Ikeda

Morita

2008

Diseases of the Esophagus

Self Cite

View full text Add to dashboard Cite

Lipo-prostaglandin E1 (PGE1) is a new preparation of PGE1 in which it is bound to lipids in order to slow PGE1 release and delay its rate of metabolism. We investigated how long the beneficial effects of intravenous administration of lipo-PGE1 on the ischemic gastric tube continue. The gastric tube was constructed using 15 domestic pigs under general anesthesia and saline, unmodified PGE1 and lipo-PGE1 were infused continuously at a rate of 0.05 microg/kg/min for 10 minutes. Tissue blood flow (TBF) was analyzed from before administration to 120 minutes after the end of administration. There were no obvious changes in TBF during the administration of saline. However, TBF during treatment with unmodified PGE1 and lipo-PGE1 was significantly increased to 13.1 +/- 1.3 and 13.5 +/- 1.4 mL/min/100 g, respectively (paired t-test; P < 0.01). Although TBF was significantly decreased to 8.0 +/- 1.0 mL/min/100 g on 10 minutes after the end of unmodified PGE1 administration (paired t-test; P < 0.01), it was maintained over 10 mL/min/100 g until 120 minutes in lipo-PGE1 group. Lipo-PGE1 infusion leads to the objectively measurable improvement and the prolonged action in the blood perfusion of the gastric tube in pigs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Long beneficial effects after lipo-prostaglandin E1 administration on the ischemic gastric tube in pigs

Ikeda

Morita

2008

Diseases of the Esophagus

Self Cite

View full text Add to dashboard Cite

show abstract

“…A placebo-controlled 1-year study with 41 normotensive type 1 or type 2 diabetic patients with mild neuropathy receiving the angiotensinconverting enzyme inhibitor trandolapril resulted in an improvement of NCV, whereas vibration-perception threshold, autonomic function, and the neuropathy symptom and deficit score did not change compared to control subjects [35]. Treatment of 364 diabetic patients with neuropathy or leg ulcers with prostaglandin E 1 (PGE 1 ) incorporated in lipid microspheres (lipo-PGE 1 ) for 4 weeks improved motor conduction velocity [36]. Furthermore, lipo-PGE administration reduced elevated circulating plasma ET-1 levels.…”

Section: Vascular Dysfunctionmentioning

confidence: 94%

New treatments for diabetic neuropathy: Pathogenetically oriented treatment

et al. 2003

View full text Add to dashboard Cite

Although there is clear evidence from experimental diabetic neuropathy (DN) models that the multiple pathways involved in neuronal degeneration cause overproduction of reactive oxygen species, oxidative stress, and cellular dysfunction, therapeutic approaches addressing these mechanisms have not yet provided a basis for a successful treatment of patients with DN. This review discusses the current knowledge on the pathomechanisms of unchecked reactive oxygen species accumulation, implications for specific treatment, and the need for carefully designed experimental studies and clinical trials closing the gap between promising results in experimental DN and its implementation into a pathogenetically oriented treatment.

show abstract

“…82 Prostaglandin analogs may be effective by increasing the endoneurial blood flow. 83 The mainstay of treatment currently remains symptomatic with the use of tricyclic antidepressants, serotonin reuptake inhibitors, and ion channel blockers.…”

Section: Treatmentmentioning

confidence: 99%

Diabetic Neuropathies

Sinnreich

Taylor

Dyck³

2005

The Neurologist

167

View full text Add to dashboard Cite

Diabetes mellitus is associated with a wide spectrum of neuropathy syndromes, ranging from a mild asymptomatic distal sensory neuropathy to a severe disabling radiculoplexus neuropathy. As the pathophysiology of these separate conditions is better understood, classification of the various phenotypes becomes important because of treatment implications. Here we provide a short summary of the history of the classification of diabetic neuropathies and try to describe the most common forms classified according to their presumed pathophysiology. We have tried to include epidemiological data where available, as well as histopathology of nerve in several diabetic neuropathies.

show abstract

Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: Placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers

Cited by 45 publications

References 21 publications

Long beneficial effects after lipo-prostaglandin E1 administration on the ischemic gastric tube in pigs

Long beneficial effects after lipo-prostaglandin E1 administration on the ischemic gastric tube in pigs

New treatments for diabetic neuropathy: Pathogenetically oriented treatment

Diabetic Neuropathies

Contact Info

Product

Resources

About